[Cost-effectiveness of human papillomavirus vaccination in South Korea]

Lee YJ, Kim JM, Park JY, Kim YJ, Kim Y
Record ID 32013000523
Authors' objectives: The purpose of this study is to provide evidence for rational decision making through conducting the economic evaluation of HPV vaccine by societal perspective.
Authors' recommendations: Based on the assumption that the cost of the vaccine after introduction of the vaccination program would decrease to 70% of its current price, the incremental cost-effectiveness ratio of the vaccination of 13-year-old girls was $32,000 per quality-adjusted life-year (QALY) gained, as compared with the current screening practice. Therefore, the vaccination program is not cost-effective in Korea given the cost-effectiveness threshold of GDP per capita ($23,680). The sensitivity analysis showed that the price, the effectiveness of vaccination and discount rate affected the result.
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: South Korea
MeSH Terms
  • Humans
  • Papillomavirus Vaccines
  • Korea
  • Papillomavirus Infections
  • Cost-Benefit Analysis
Organisation Name: National Evidence-based healthcare Collaborating Agency
Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name: int@neca.re.kr
Contact Email: int@neca.re.kr
Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.